Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
J Hepatol. 2021 Jun;74(6):1398-1406. doi: 10.1016/j.jhep.2020.12.021. Epub 2021 Jan 13.
BACKGROUND & AIMS: Liver transplant priority in the US and Europe follows the 'sickest-first' principle. However, for patients with hepatocellular carcinoma (HCC), priority is based on binary tumor criteria to expedite transplant for patients with 'acceptable' post-transplant outcomes. Newer risk scores developed to overcome limitations of these binary criteria are insufficient to be used for waitlist priority as they focus solely on HCC-related pre-transplant variables. We sought to develop a risk score to predict post-transplant survival for patients using HCC- and non-HCC-related variables.
We performed a retrospective cohort study using national registry data on adult deceased-donor liver transplant (DDLT) recipients with HCC from 2/27/02-12/31/18. We fit Cox regression models focused on 5- and 10-year survival to estimate beta coefficients for a risk score using manual variable selection. We then calculated absolute predicted survival time and compared it to available risk scores.
Among 6,502 adult DDLT recipients with HCC, 11 variables were selected in the final model. The AUCs at 5- and 10-years were: 0.62, 95% CI 0.57-0.67 and 0.65, 95% CI 0.58-0.72, which was not statistically significantly different to the Metroticket and HALT-HCC scores. The LiTES-HCC score was able to discriminate patients based on post-transplant survival among those meeting Milan and UCSF criteria.
We developed and validated a risk score to predict post-transplant survival for patients with HCC. By including HCC- and non-HCC-related variables (e.g., age, chronic kidney disease), this score could allow transplant professionals to prioritize patients with HCC in terms of predicted survival. In the future, this score could be integrated into survival benefit-based models to lead to meaningful improvements in life-years at the population level.
We created a risk score to predict how long patients with liver cancer will live if they get a liver transplant. In the future, this could be used to decide which waitlisted patients should get the next transplant.
美国和欧洲的肝移植优先级遵循“先救病重者”的原则。然而,对于肝细胞癌(HCC)患者,优先级是基于二元肿瘤标准,以加快对“可接受”移植后结果的患者进行移植。为了克服这些二元标准的局限性而开发的新风险评分不足以用于候补名单优先级,因为它们仅侧重于移植前与 HCC 相关的变量。我们试图开发一种风险评分,以预测使用 HCC 和非 HCC 相关变量的移植后患者的生存情况。
我们使用全国性的 2002 年 2 月 27 日至 2018 年 12 月 31 日成人死亡供肝肝移植(DDLT)接受者 HCC 的登记数据进行回顾性队列研究。我们使用手动变量选择为风险评分拟合 Cox 回归模型,以估计 5 年和 10 年生存率的β系数。然后,我们计算了绝对预测生存时间,并将其与现有风险评分进行了比较。
在 6502 名患有 HCC 的成人 DDLT 接受者中,最终模型中选择了 11 个变量。5 年和 10 年的 AUC 分别为:0.62,95%CI 0.57-0.67 和 0.65,95%CI 0.58-0.72,与 Metroticket 和 HALT-HCC 评分无统计学差异。LiTES-HCC 评分能够根据米兰和 UCSF 标准的移植后生存情况来区分患者。
我们开发并验证了一种用于预测 HCC 患者移植后生存的风险评分。通过纳入 HCC 和非 HCC 相关变量(例如年龄、慢性肾脏病),该评分可以使移植专业人员根据预测的生存情况对 HCC 患者进行优先级排序。在未来,该评分可以纳入基于生存获益的模型中,从而在人群水平上带来有意义的寿命提高。
我们创建了一个风险评分来预测患有肝癌的患者如果进行肝移植能活多久。在未来,这可以用来决定哪些候补患者应该接受下一次移植。